Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
What it found
The trial ended early for another reason (see below).
Reason given: Inadequate recruitment; termination of funding
What was tested
Treatment tested
- Acetazolamide
Carbonic anhydrase I inhibitor|Carbonic anhydrase II inhibitor|Carbonic anhydrase IV inhibitor|Carbonic anhydrase XII inhibitor
Placebo
- Placebo
Results by group
Percent Change in Global Cerebral Blood Flow
baseline, 24 weeks
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| Acetazolamide | 22.9 percent change | 16.2 (Standard Deviation) | 5 |
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| Acetazolamide | 5 | 0 (0.0%) | 0 |
| Placebo | 0 | 0 | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Percent Change in Global Cerebral Blood Flow
baseline, 24 weeks
MRI lesions
Other measures (2)
Percent Change in Tissue Integrity in White Matter (Mean Diffusivity)
baseline, 24 weeks
MRI lesionsPercent Change in Tissue Integrity in White Matter (Fractional Anisotropy)
baseline, 24 weeks
MRI lesions
Who could take part
Relapsing MS · 18 to 55 · EDSS 0 to 6.0
Show the full criteria
Inclusion criteria
1. Diagnosis of relapsing forms of multiple sclerosis using revised McDonald criteria 2. Stable on any FDA-approved disease-modifying therapy. The term "stable" implies that the subject has not had change in therapy for any reason for the 6 months prior to study entry. 3. Expanded Disability Status Scale (EDSS) score of 0-6.0 inclusive 4. Understood and signed written informed consent, obtained prior to the study subject undergoing any study related procedure, including screening tests.
Exclusion criteria
1. Known hypersensitivity to sulfonamides or derivatives 2. Known history of renal or hepatic disease, cerebrovascular disease including stroke, transient ischemic attack, myocardial infarction, angina or congestive heart failure. 3. Evidence to suggest hyponatremia or hypokalemia, marked kidney dysfunction defined as creatinine greater than 2.0 mg/dL or liver disease dysfunction defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three-fold upper limit of normal (ULN). 4. Evidence to suggest suprarenal gland failure. 5. Evidence of hyperchloremic acidosis. 6. Initiation of new immunosuppressant treatment after the subject becomes protocol-eligible (except for corticosteroids) or enrollment in a concurrent trial. 7. Prior treatment with mitoxantrone, natalizumab, methotrexate, cladribine cyclophosphamide or other change in disease modifying therapy (DMT) within 6 months of initiation of study. 8. Subjects with any history of cytopenia. 9. History of pulmonary obstruction or emphysema. 10. Active hepatitis B or hepatitis C infection or evidence of cirrhosis. 11. Human immunodeficiency virus (HIV) positivity. 12. Uncontrolled diabetes mellitus defined as HbA1c>8% and/or requiring intensive management. 13. Uncontrolled viral, fungal, or bacterial infection (excluding asymptomatic bacteriuria). 14. Any condition that, in the opinion of the investigators, would jeopardize the ability of the subject to tolerate treatment with ACZ. 15. Prior history of malignancy. 16. Positive pregnancy test or inability or unwillingness to use effective means of birth control. Effective birth control defines as: * Refraining from all acts of vaginal intercourse (abstinence) * Consistent use of birth control pills * Tubal sterilization or male partner who has undergone vasectomy * Placement of an intrauterine device (IUD) * Use, with every act of intercourse, of a diaphragm with contraceptive jelly and/or condoms with contraceptive foam 17. Presence of metallic objects implanted in the body that would preclude the ability of the subject to safely have MRI exams. 18. Psychiatric illness, mental deficiency, or cognitive dysfunction making compliance with treatment of informed consent impossible.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study will evaluate how improved cerebral blood flow affects the way in which newly formed MS lesions evolve and whether tissue repair is improved. Patients with multiple sclerosis (MS) will be treated with acetazolamide in daily divided doses and obtain MRI to determine how much and in which regions of the brain cerebral perfusion improves as well as the extent to which tissue integrity is improved in these areas.
Papers
Loading reviews and guidelines…
History
Started
Aug 2016
Main results due
Feb 2022
Finished
Feb 2022
Results posted
Mar 2023